Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Emmaus Life Sciences Inc (EMMA)

Emmaus Life Sciences Inc (EMMA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Dr. Niihara Meets with Local Indian Governor

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), announced today that Dr. Yutaka Niihara, Chairman and Chief Executive Officer of the company, was...

EMMA : 0.4900 (+22.50%)
Dr. Niihara Feted by Indian Government in Recognition of the Development of Endari®

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), announced today that Dr. Yutaka Niihara, Chairman and Chief Executive Officer of the company, was...

EMMA : 0.4900 (+22.50%)
Endari® Receives Kuwaiti Marketing Authorization

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, announced today that it has received Registration Approval...

EMMA : 0.4900 (+22.50%)
Emmaus Life Sciences Receives Endari® Marketing Authorization from the Qatar Ministry of Public Health

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that it has been issued a Registration...

EMMA : 0.4900 (+22.50%)
Emmaus Life Sciences Reports Q3 2022 Financial Results and Provides Business Update

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...

EMMA : 0.4900 (+22.50%)
Emmaus Life Sciences Announces Collaboration with Kier (Junior) Spates to Share Personal Experience with Sickle Cell Disease and Endari®

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA) a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today...

EMMA : 0.4900 (+22.50%)
Emmaus Life Sciences Reports Q2 2022 Financial Results and Provides Business Update

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...

EMMA : 0.4900 (+22.50%)
Emmaus Life Sciences Announces Engagement of Strategic Business Relations and Professional Services Advisor

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...

EMMA : 0.4900 (+22.50%)
Q4 Investor Summit Small Cap & Micro Cap Conference To Offer Opportunity to Meet with C-level Management of 90+ Companies

Small and Micro-cap investors are invited to attend the Q4 Investor Summit being held on November 16-17, 2021. The event is organized by the Investor Summit Group, recognised as a highly reputed brand...

AZ.TO : 6.19 (unch)
AAZZF : 10.8545 (+0.13%)
ACST : 0.7141 (-1.04%)
ATNM : 11.56 (+1.05%)
ADCO.TO : 0.2600 (unch)
ADCOF : 0.1960 (-4.30%)
ALIM : 2.60 (-2.26%)
ACOGF : 0.3147 (+13.73%)
AMST : 0.3444 (+22.56%)
ANVS : 15.25 (+11.31%)
ANPC : 8.51 (-4.17%)
ARC : 3.43 (-0.29%)
Emmaus Life Sciences Acquires Key Intellectual Property Rights to Novel IRAK4 Inhibitor From Kainos Medicine

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...

EMMA : 0.4900 (+22.50%)

Barchart Exclusives

Is Corn Ready for a Seasonal February Rally?
After correcting a portion of the recent rally off the seasonal lows, corn appears to be ready to resume its post-harvest rally, as February has historically seen the uptrend continue into the first week of March. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar